Gilead Sciences | GILD - Assets


Gilead Sciences reported $56.28B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 7.34B 381.14M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026